Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors (2017)
- Authors:
- USP affiliated authors: SILVA, ALFREDO RIBEIRO DA - FMRP ; ANDRADE, JURANDYR MOREIRA DE - FMRP ; CARRARA, HELIO HUMBERTO ANGOTTI - FMRP ; TIEZZI, DANIEL GUIMARÃES - FMRP
- Unidade: FMRP
- DOI: 10.1590/1414-431x20165674
- Subjects: NEOPLASIAS MAMÁRIAS; QUIMIOTERAPIA ADJUVANTE; PROGNÓSTICO
- Keywords: Neoadjuvant chemotherapy; Trastuzumab; Pathologic complete response; Predictive factors of response; Prognosis
- Language: Inglês
- Imprenta:
- Publisher place: Ribeirão Preto
- Date published: 2017
- Source:
- Título: Brazilian Journal of Medical and Biological Research
- ISSN: 0100-879X
- Volume/Número/Paginação/Ano: v. 50, n. 2, art. 5674, 2017
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
BUZATTO, I. P. C. et al. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, v. 50, n. 2, 2017Tradução . . Disponível em: https://doi.org/10.1590/1414-431x20165674. Acesso em: 12 fev. 2026. -
APA
Buzatto, I. P. C., Ribeiro-Silva, A., Andrade, J. M. de, Carrara, H. H. A., & Tiezzi, D. G. (2017). Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Brazilian Journal of Medical and Biological Research, 50( 2). doi:10.1590/1414-431x20165674 -
NLM
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2026 fev. 12 ] Available from: https://doi.org/10.1590/1414-431x20165674 -
Vancouver
Buzatto IPC, Ribeiro-Silva A, Andrade JM de, Carrara HHA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors [Internet]. Brazilian Journal of Medical and Biological Research. 2017 ; 50( 2):[citado 2026 fev. 12 ] Available from: https://doi.org/10.1590/1414-431x20165674 - Quality of life in women with breast cancer treated with or without chemotherapy
- Cancer stem cells and lymph node metastasis in early stage breast cancer
- Trastuzumab use during pregnancy: long-term survival after locally advanced breast cancer and long-term infant follow-up
- Clinicopathological characteristics and recurrence risk in patients with ductal carcinoma in situ of the breast
- Idade como fator independente de prognóstico no câncer de mama
- Tumor neuroendócrino primário de mama: relato de três casos e revisão de literatura
- Taxane-based chemotherapy enhances response to neoadjuvant treatment for stage II and III breast cancer
- Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
Informações sobre o DOI: 10.1590/1414-431x20165674 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
002891231.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
